Your browser doesn't support javascript.
loading
Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D2EFT.
Papot, Emmanuelle; Jacoby, Simone; Arlinda, Dona; Avihingsanon, Anchalee; Azwa, Iskandar; Borok, Margaret; Brown, Dannae; Cissé, Mohamed; Dao, Sounkalo; Eriobu, Nnakelu; Kaplan, Richard; Karyana, Muhammad; Kumarasamy, Nagalingeswaran; Lee, Johnnie; Losso, Marcelo H; Matthews, Gail V; Perelis, Leonardo; Perez-Casas, Carmen; Ruxrungtham, Kiat; Watkins, Melynda; Lane, H Clifford; Kelleher, Anthony; Law, Matthew; Polizzotto, Mark N.
Afiliação
  • Papot E; Therapeutic and Vaccine Research Program, The Kirby Institute, University of New South Wales Sydney, Sydney, NSW, Australia.
  • Jacoby S; Therapeutic and Vaccine Research Program, The Kirby Institute, University of New South Wales Sydney, Sydney, NSW, Australia.
  • Arlinda D; Indonesia Research Partnership on Infectious Disease, Jakarta, Indonesia.
  • Avihingsanon A; The HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
  • Azwa I; Infectious Diseases Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • Borok M; University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.
  • Brown D; Global Medical, ViiV Healthcare, Abbotsford, Australia.
  • Cissé M; Faculté des Sciences et techniques de la santé de l'Université Gamal Abdel Nasser de Conakry, University hospital of Donka, Conakry, Guinea.
  • Dao S; University Clinical Research Centre, Bamako, Mali.
  • Eriobu N; Institute of Human Virology, Abuja, Nigeria.
  • Kaplan R; Desmond Tutu Health Foundation, Cape Town, South Africa.
  • Karyana M; Indonesia Research Partnership on Infectious Disease, Jakarta, Indonesia.
  • Kumarasamy N; Chennai Antiviral Research and Treatment Clinical Research Site, Infectious Diseases Medical Centre, Voluntary Health Services, Chennai, India.
  • Lee J; Global Medical Affairs, Global Public Health, Janssen Pharmaceutical companies of Johnson & Johnson, Plainfield, NJ, USA.
  • Losso MH; Coordinación en Investigación Clínica Académica en Latinoamérica Fundación IBIS Buenos Aires, Buenos Aires, Argentina.
  • Matthews GV; Therapeutic and Vaccine Research Program, The Kirby Institute, University of New South Wales Sydney, Sydney, NSW, Australia.
  • Perelis L; Coordinación en Investigación Clínica Académica en Latinoamérica Fundación IBIS Buenos Aires, Buenos Aires, Argentina.
  • Perez-Casas C; Unitaid, Geneva, Switzerland.
  • Ruxrungtham K; The HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
  • Watkins M; Product Development and Regulatory Affairs, Clinton Health Access Initiative, Boston, MA, USA.
  • Lane HC; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Kelleher A; Immunovirology and Pathogenesis Program, The Kirby Institute, University of New South Wales Sydney, Sydney,Australia.
  • Law M; Biostatistics and Databases Program, The Kirby Institute, University of New South Wales Sydney, Sydney,Australia.
  • Polizzotto MN; Therapeutic and Vaccine Research Program, The Kirby Institute, University of New South Wales Sydney, Sydney, NSW, Australia.
HIV Res Clin Pract ; 23(1): 37-46, 2022 07 19.
Article em En | MEDLINE | ID: mdl-35938597
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Fármacos Anti-HIV Tipo de estudo: Guideline / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: HIV Res Clin Pract Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Fármacos Anti-HIV Tipo de estudo: Guideline / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: HIV Res Clin Pract Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália